LabTestSuperstore.
Range Atlas

AI-collected, not medically reviewed. Compare source context, not your health status.

Choose the units printed on your report.

Apolipoprotein B (ApoB): ranges and targets

9 sources / 9 ranges · mg/dL

Order test ↗

Categories and treatment goals are not interchangeable. Blank chart areas do not mean normal. Display values are rounded.

Shared scale (mg/dL)

50100150

Laboratory reference intervals

Medscape

Source reference interval

United States · Any sex · adult

Medscape adult ApoB reference range is below 130 mg/dL

Upper boundary 130 mg/dL

50100150

Arrow: continues beyond the displayed scale.

Source details: Medscape, Source reference interval
Native values:
Upper boundary 130 mg/dL
Context:
Medscape adult ApoB reference range is below 130 mg/dL
Population / collection / assay:
any; adult. Medscape adult ApoB reference range is below 130 mg/dL Any additional details not recorded here remain unspecified.
Source date/version:
Not recorded
Last verified in this pass:
Not rechecked. Recorded access: 2026-06-06.
Verification:
verified_numeric_source. Inherited extraction, not rechecked in the September 20 pass. Endpoint inclusion, source version and any context absent from the original record remain unverified.
Endpoint inclusion is not verified. A boundary label does not imply ≤ or ≥.
Locator:
Original source link and basis note
Read Medscape (new tab)

Mayo Clinic Laboratories

Source reference interval

United States · Any sex · adult

Mayo Clinic Labs lists ApoB desirable as below 90 mg/dL (adults).

Upper boundary 90 mg/dL

50100150

Arrow: continues beyond the displayed scale.

Source details: Mayo Clinic Laboratories, Source reference interval
Native values:
Upper boundary 90 mg/dL
Context:
Mayo Clinic Labs lists ApoB desirable as below 90 mg/dL (adults).
Population / collection / assay:
any; adult. Mayo Clinic Labs lists ApoB desirable as below 90 mg/dL (adults). Any additional details not recorded here remain unspecified.
Source date/version:
Not recorded
Last verified in this pass:
Not rechecked. Recorded access: 2026-06-11.
Verification:
verified_numeric_source. Inherited extraction, not rechecked in the September 20 pass. Endpoint inclusion, source version and any context absent from the original record remain unverified.
Endpoint inclusion is not verified. A boundary label does not imply ≤ or ≥.
Locator:
Original source link and basis note
Read Mayo Clinic Laboratories (new tab)

Clinical categories and treatment goals

Cleveland Clinic

Source category

United States · Any sex · adult

Cleveland Clinic says ApoB above 130 mg/dL is higher risk

Lower boundary 130 mg/dL

50100150

Arrow: continues beyond the displayed scale.

Source details: Cleveland Clinic, Source category
Native values:
Lower boundary 130 mg/dL
Context:
Cleveland Clinic says ApoB above 130 mg/dL is higher risk
Population / collection / assay:
any; adult. Cleveland Clinic says ApoB above 130 mg/dL is higher risk Any additional details not recorded here remain unspecified.
Source date/version:
Not recorded
Last verified in this pass:
Not rechecked. Recorded access: 2026-06-06.
Verification:
verified_numeric_source. Inherited extraction, not rechecked in the September 20 pass. Endpoint inclusion, source version and any context absent from the original record remain unverified.
Endpoint inclusion is not verified. A boundary label does not imply ≤ or ≥.
Locator:
Original source link and basis note
Read Cleveland Clinic (new tab)

Singapore Academy of Medicine lipid guideline

Source treatment goal

Singapore · Any sex · adult

Singapore lipid guideline lists ApoB target below 65 mg/dL for very high risk patients

Upper boundary 65 mg/dL

50100150

Arrow: continues beyond the displayed scale.

Source details: Singapore Academy of Medicine lipid guideline, Source treatment goal
Native values:
Upper boundary 65 mg/dL
Context:
Singapore lipid guideline lists ApoB target below 65 mg/dL for very high risk patients
Population / collection / assay:
any; adult. Singapore lipid guideline lists ApoB target below 65 mg/dL for very high risk patients Any additional details not recorded here remain unspecified.
Source date/version:
Not recorded
Last verified in this pass:
Not rechecked. Recorded access: 2026-06-06.
Verification:
verified_numeric_source. Inherited extraction, not rechecked in the September 20 pass. Endpoint inclusion, source version and any context absent from the original record remain unverified.
Endpoint inclusion is not verified. A boundary label does not imply ≤ or ≥.
Locator:
Original source link and basis note
Read Singapore Academy of Medicine lipid guideline (new tab)

ESC guideline hosted by Swiss cardiovascular society

Source treatment goal

Switzerland · Any sex · adult

Swiss-hosted ESC prevention document supports an ApoB target around 70 mg/dL

Upper boundary 70 mg/dL

50100150

Arrow: continues beyond the displayed scale.

Source details: ESC guideline hosted by Swiss cardiovascular society, Source treatment goal
Native values:
Upper boundary 70 mg/dL
Context:
Swiss-hosted ESC prevention document supports an ApoB target around 70 mg/dL
Population / collection / assay:
any; adult. Swiss-hosted ESC prevention document supports an ApoB target around 70 mg/dL Any additional details not recorded here remain unspecified.
Source date/version:
Not recorded
Last verified in this pass:
Not rechecked. Recorded access: 2026-06-06.
Verification:
verified_numeric_source. Inherited extraction, not rechecked in the September 20 pass. Endpoint inclusion, source version and any context absent from the original record remain unverified.
Endpoint inclusion is not verified. A boundary label does not imply ≤ or ≥.
Locator:
Original source link and basis note
Read ESC guideline hosted by Swiss cardiovascular society (new tab)

Surrey Cardiovascular Clinic UK target table

Source treatment goal

United Kingdom · Any sex · adult

UK clinician table gives an ApoB low-risk target at or below 100 mg/dL

Upper boundary 100 mg/dL

50100150

Arrow: continues beyond the displayed scale.

Source details: Surrey Cardiovascular Clinic UK target table, Source treatment goal
Native values:
Upper boundary 100 mg/dL
Context:
UK clinician table gives an ApoB low-risk target at or below 100 mg/dL
Population / collection / assay:
any; adult. UK clinician table gives an ApoB low-risk target at or below 100 mg/dL Any additional details not recorded here remain unspecified.
Source date/version:
Not recorded
Last verified in this pass:
Not rechecked. Recorded access: 2026-06-06.
Verification:
verified_numeric_source. Inherited extraction, not rechecked in the September 20 pass. Endpoint inclusion, source version and any context absent from the original record remain unverified.
Endpoint inclusion is not verified. A boundary label does not imply ≤ or ≥.
Locator:
Original source link and basis note
Read Surrey Cardiovascular Clinic UK target table (new tab)

Heartcare Sydney

Source treatment goal

Australia · Any sex · adult

Australian cardiology source gives a general-population ApoB target below 1.0 g/L or 100 mg/dL

Upper boundary 100 mg/dL

50100150

Arrow: continues beyond the displayed scale.

Source details: Heartcare Sydney, Source treatment goal
Native values:
Upper boundary 100 mg/dL
Context:
Australian cardiology source gives a general-population ApoB target below 1.0 g/L or 100 mg/dL
Population / collection / assay:
any; adult. Australian cardiology source gives a general-population ApoB target below 1.0 g/L or 100 mg/dL Any additional details not recorded here remain unspecified.
Source date/version:
Not recorded
Last verified in this pass:
Not rechecked. Recorded access: 2026-06-06.
Verification:
verified_numeric_source. Inherited extraction, not rechecked in the September 20 pass. Endpoint inclusion, source version and any context absent from the original record remain unverified.
Endpoint inclusion is not verified. A boundary label does not imply ≤ or ≥.
Locator:
Original source link and basis note
Read Heartcare Sydney (new tab)

Named clinician and other published views

Peter Attia

Approximate ApoB ceiling

Named view · Any sex · adult

Named clinician view on early, aggressive ApoB reduction; not a universal treatment target or laboratory interval.

Approximately Upper boundary 60 mg/dL

50100150

Arrow: continues beyond the displayed scale.

Source details: Peter Attia, Approximate ApoB ceiling
Native values:
Approximately Upper boundary 60 mg/dL
Context:
Peter Attia's discussion of early, aggressive ApoB reduction. A named clinician view, not a universal treatment target or laboratory interval.
Population / collection / assay:
any; adult. Named clinician view on early, aggressive ApoB reduction; not a universal treatment target or laboratory interval. Any additional details not recorded here remain unspecified.
Source date/version:
2022-04-15
Last verified in this pass:
2026-09-20. Recorded access: 2026-09-20.
Verification:
verified_numeric_source. Publisher-hosted text checked September 20, 2026. Not a medical review.
Approximate source wording, not an exact mathematical cutoff.
Locator:
Show Notes: Cardiovascular disease, approximate ceiling
Read Peter Attia (new tab)

Rawmarkers longevity medicine summary

Published view

Named view · Any sex · adult

Rawmarkers summarizes a longevity-focused ApoB target below 70 mg/dL

Upper boundary 70 mg/dL

50100150

Arrow: continues beyond the displayed scale.

Source details: Rawmarkers longevity medicine summary, Published view
Native values:
Upper boundary 70 mg/dL
Context:
Rawmarkers summarizes a longevity-focused ApoB target below 70 mg/dL
Population / collection / assay:
any; adult. Rawmarkers summarizes a longevity-focused ApoB target below 70 mg/dL Any additional details not recorded here remain unspecified.
Source date/version:
Not recorded
Last verified in this pass:
Not rechecked. Recorded access: 2026-06-06.
Verification:
verified_numeric_source. Inherited extraction, not rechecked in the September 20 pass. Endpoint inclusion, source version and any context absent from the original record remain unverified.
Endpoint inclusion is not verified. A boundary label does not imply ≤ or ≥.
Locator:
Original source link and basis note
Read Rawmarkers longevity medicine summary (new tab)

Units change the display, not the source population or clinical purpose. Source-native values remain in each disclosure. Source comparison in common US units

Methodology, units and limitations

AI-collected source-comparison prototype. Not medically reviewed. Not a diagnostic tool. Reference intervals describe a source population; categories and treatment goals have different purposes. Named views do not establish a universal optimum. Country identifies a source, not a biological normal for everyone there.

Source counts use stable publisher IDs; one source may supply several legitimate categories. Source dates and recorded access dates are separate. Older rows explicitly marked not rechecked have not received a new source review. Missing age, fasting, assay and risk details are not inferred.

Strict < and > differ from inclusive ≤ and ≥. Approximate and unknown boundaries are labeled, not converted into exact cutoffs. Printed endpoint precision is preserved; gaps between source categories are not silently filled.

Bars show only the visible portion of each interval. Arrows indicate continuation; small intervals are not enlarged to imply a wider range. Display rounding does not change stored values. Numerically equivalent units do not change the numbers.

Personal-result entry is not available in this release. Do not enter health results into the marker finder. The tool does not classify you, recommend treatment or adjust ranges for your age.